On the September 22 broadcast of Mayo Clinic Radio, Yi Lin, M.D., Ph.D., a hematologist at Mayo Clinic and Chair of the Cellular Therapeutics Cross-Disciplinary Group in the Mayo Clinic Cancer Center, explained how chimeric antigen receptor T-cell therapy (CAR T-cell therapy) works and where the research is headed.
In this new cancer treatment, cells in the immune system, known as T cells, are genetically modified to equip them to recognize and destroy cancer cells. CAR T-cell therapy was approved by the U.S. Food and Drug Administration (FDA) last year to treat two types of blood cancer—relapsed B-cell acute lymphoblastic leukemia and relapsed B-cell non-Hodgkin lymphoma. Less than 15% of people who experience recurrence of those cancers respond completely to existing treatments. Up to 90% of people respond to CAR T-cell therapy, with 40% to 50% experiencing remission.
Dr. Lin discussed how CAR T-cell therapy works, new research and developments, and which patients use CAR T-cell therapy and how they recover.
Listen to the Podcast
To listen to the interview, the radio segment featuring Dr. Lin begins at 1:00 and runs through 18:30. If you have time, the full show also has Charanjit Rihal, M.D., an interventional cardiologist at Mayo Clinic, discussing treatment and prevention of coronary artery disease. And Nipunie Rajapakse, M.D., an infectious diseases specialist at Mayo Clinic, sharing tips on how to help kids avoid common infections.